Staphylococcus aureus pneumonia: Emergence of MRSA in the community

Seminars in Respiratory and Critical Care Medicine

Volumn 26, Issue 6, 2005, Pages 643-649

  Bradley, Suzanne F ^a,b  

^a VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Methicillin resistance; Pneumonia; Staphylococci

Indexed keywords

CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DROTRECOGIN; ERYTHROMYCIN; IMIPENEM; LINCOSAMIDE; LINEZOLID; MACROLIDE; OXAZOLIDINONE DERIVATIVE; PANTON VALENTINE LEUKOCIDIN; RIFAMPICIN; STAPHYLOCOCCUS TOXIN; STREPTOGRAMIN; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG; VANCOMYCIN;

BACTERIAL PNEUMONIA; BACTERIAL STRAIN; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; EPIDEMIC; HUMAN; INFECTION CONTROL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STAPHYLOCOCCUS AUREUS;

COMMUNITY-ACQUIRED INFECTIONS; HUMANS; METHICILLIN RESISTANCE; PNEUMONIA, BACTERIAL; PREVALENCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 30344487574     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-925528     Document Type: Review

References (61)

1. Garner JS, Jarvis WR, Emori TG, et al. CDC definitions for nosocomial infections. Am J Infect Control 1988;16:128-140
2. Cookson BD. Methicillin-resistant Staphylococcus aureus in the community: new battlefronts, or are the battles lost? Infect Control Hosp Epidemiol 2000;21:398-403
3. Zetola N, Francis JS, Nuermberger EL, Bishai WR. Community-acquired methicillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis 2005;5:275-286
4. Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin Infect Dis 2003;36:131-139
5. Saravolatz LD, Pohlod DJ, Arking LM. Community-acquired methicillin-resistant Staphylococcus aureus infections: a new source for nosocomial outbreaks. Ann Intern Med 1982;97:325-329
6. Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus: Minnesota and North Dakota, 1997-1999. Morb Mortal Wkly Rep 1999;48:707-710
7. Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998;279:593-598
8. Said-Salim B, Mathema B, Kreiswirth BN. Community-acquired methicillin-resistant Staphylococcus aureus: an emerging pathogen. Infect Control Hosp Epidemiol 2003;4:451-455
9. Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin Infect Dis 2005;40:562-573
10. Mongkolrattanothai K, Boyle S, Kahanna MD, et al. Severe Staphylococcus aureus infections caused by clonally related community-acquired methicillin-susceptible and methicillin-resistant isolates. Clin Infect Dis 2003;37:1050-1058
11. Chambers HF. Community-associated MRSA-resistance and virulence converge. N Engl J Med 2005;352:1485-1487
12. Urth T, Juul G, Skov R, et al. Spread of methicillin-resistant Staphylococcus aureus ST80-IV clone in a Danish community. Infect Control Hosp Epidemiol 2005;26:144-149
13. Hausmann W, Karlish AJ. Staphylococcal pneumonia in adults. BMJ 1956;2:845-847
14. Kaye MG, Fox MJ, Bartlett JG, et al. The clinical spectrum of Staphylococcus aureus pulmonary infection. Chest 1990;97: 788-792
15. Laupland KB, Church DL, Mucenski M, et al. Population-based study of the epidemiology of and the risk factors for invasive Staphylococcus aureus infections. J Infect Dis 2003;187: 1452-1459
16. Musher DM, Lamm N, Darouiche RO, et al. The current spectrum of Staphylococcus aureus infection in a tertiary care hospital. Medicine 1994;73:186-208
17. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus in three communities. N Engl J Med 2005;352:1436-1444
18. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003;290:2976-2984
19. Chickering HT, Park JH. Staphylococcus aureus pneumonia. JAMA 1919;72:617-626
20. Ede S, Davis GM, Holmes FH. Staphylococcic pneumonia. JAMA 1959;170:638-643
21. Reimann HA. Primary Staphylococcic pneumonia. JAMA 1933;101:514-520
22. Gallis HA. Subacute staphylococcal pneumonia in renal transplant recipient. Am Rev Respir Dis 1975;112:109-112
23. Watanakunakorn C. Bacteremic Staphylococcus aureus pneumonia. Scand J Infect Dis 1987;19:623-627
24. Wiita RM, Cartwright RR, Davis JG. Staphylococcal pneumonia in adults: a review of 102 cases. Am J Roentgenol 1961;86:1083-1091
25. Bentley DW. Staphylococcal pneumonia: coping with a medical emergency. J Respir Dis 1980;1:23-41
26. Naraqi S, McDonnell G. Hematogenous staphylococcal pneumonia secondary to soft tissue infection. Chest 1981; 79:173-175
27. Musher DM, Franco M. Staphylococcal pneumonia: a new perspective. Chest 1981;79:172-173
28. Fisher AM, Trever RW, Curtin JA, et al. Staphylococcal pneumonia: a review of 21 cases in adults. N Engl J Med 1958;256:919-928
29. Johnston BL. Methicillin-resistant Staphylococcus aureus as a cause of community-acquired pneumonia: a critical review. Semin Respir Infect 1994;9:199-206
30. Cafferkey MT, Abrahamson E, Bloom A, et al. Pulmonary infection due to methicillin-resistant Staphylococcus aureus. Scand J Infect Dis 1988;20:297-301
31. Gonzalez C, Rubio M, Romero-Vivas J, et al. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999;29:1171-1177
32. Rello J, Torres A, Ricart M, et al. Ventilator-associated pneumonia by Staphylococcus aureus: comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med 1994;150:1545-1549
33. Healy CM, Hulten KG, Palazzi DL, et al. Emergence of new strains of methicillin-resistant Staphylococcus aureus in a neonatal intensive care unit. Clin Infect Dis 2004;39:1460-1466
34. Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005;40:100-107
35. Dufour P, Gillet Y, Bes M, et al. Community-acquired methicillin- resistant Staphylococcus aureus infections in France: Emergence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis 2002;35:819-824
36. Kravitz GR, Dries DJ, Peterson ML, et al. Purpura fulminans due to Staphylococcus aureus. Clin Infect Dis 2005;40:941-947
37. Gillet Y, Issartel B, Vanhems P, et al. Association between lethal Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotizing pneumonia in young immunocompetent patients. Lancet 2002;359: 753-759
38. Boussaud V, Parrot A, Mayaud C, et al. Life-threatening hemoptysis in adults with community-acquired pneumonia due to Panton-Valentine leukocidin-secreting Staphylococcus aureus. Intensive Care Med 2003;29:1840-1843
39. Le Thomas I, Mariani-Kurkdjian P, Collignon A, et al. Breast milk transmission of a Panton-Valentine leukocidin-producing Staphylococcus aureus strain causing infantile pneumonia. J Clin Microbiol 2001;39:728-729
40. Hsu L-Y, Koh T-H, Kurup A, et al. High incidence of Panton-Valentine leukocidin-producing Staphylococcus aureus in a tertiary care public hospital in Singapore. Clin Infect Dis 2005;40:486-489
41. Panton PN, Valentine FCO. Staphylococcal toxin. Lancet 1932;1:506-508
42. Lina G, Piemont Y, Godall-Gamot F, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999;29:1128-1132
43. Chambers HF. Staphylococcal purpura fulminans: a toxin-mediated disease? Clin Infect Dis 2005;40:948-950
44. Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005;352:1445-1453
45. Fowler VG, Li J, Corey RG, et al. Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients. J Am Coll Cardiol 1997;30:1072-1078
46. Moise PA, Schentag JJ. Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infection. Int J Antimicrob Agents 2000;16:S31-S34
47. Georges H, Leroy O, Alfandari S, et al. Pulmonary disposition of vancomycin in critically ill patients. Eur J Clin Microbiol Infect Dis 1997;16:385-388
48. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003;138:135-142
49. Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002;34:1481-1490
50. Kollef MH, Rello J, Cammarata SK, et al. Clinical cure and survival in gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004;30:388-394
51. Rubinstein E, Cammarata SK, Oliphant TH, et al. Linezolid (PNU-10076) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32:402-412
52. Wunderink RG, Rello J, Cammarata SK, et al. Linezolid versus vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003;124:1789-1797
53. Powers JH, Ross DB, Lin D, et al. Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2004;126:314-316
54. Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis 2003;36:473-481
55. Fagon J-Y, Patrick H, Haas DW, et al. Treatment of gram-positive nosocomial pneumonia: prospective randomized comparison of quinupristin/ dalfopristin versus vancomycin. Am J Respir Crit Care Med 2000;161:753-762
56. Scotton PG, Rigoli R, Vaglia A. Combination of quinupristin/ dalfopristin and glycopeptide in severe methicillin-resistant staphylococcal infections failing previous glycopeptide regimens. Infection 2002;30:161-163
57. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004;38:994-1000
58. Adra M, Lawrence KR. Trimethoprim-sulfamethoxazole for treatment of severe Staphylococcus aureus infections. Ann Pharmacother 2004;38:338-341
59. Ruhe JJ, Monson T, Bradsher RW, Menon A. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis 2005;40:1429-1434
60. Lewis JS, Jorgensen JH. Inducible clindamycin resistance in staphylococci: should clinicians and microbiologists be concerned. Clin Infect Dis 2005;40:280-285
61. Gauduchon V, Cozon G, Vandenesch F, et al. Neutralization of Staphylococcus aureus Panton-Valentine leukocidin by intravenous immunoglobulin in vitro. J Infect Dis 2004;189: 346-353